Elan: No new PML cases in Tysabri evaluation

Pharmaceutical company Elan has said a safety evaluation of multiple sclerosis (MS) and Crohn's disease drug Tysabri in MS patients resulted in no new confirmed cases of potentially fatal progressive multifocal leukoencephalopathy (PML).

More than 2,000 MS patients from clinical trials were eligible for the safety evaluation. To date, 91% of these MS patients participated in the safety evaluation. The remaining 9% of patients did not participate in the safety review.